Skip to main content
. 2016 Nov 25;8(3):4875–4887. doi: 10.18632/oncotarget.13608

Figure 6. Blocking peptide experiments for pARS578 are shown.

Figure 6

The top row represents the positive control i.e. IHC conducted with each AR phosphospecific antibody as indicated. The bottom row represents antibodies to AR phosphorylation sites pre-incubated with pARS578 peptide. The specific peptide utilised is boxed in red. No staining is demonstrated when the pARS578 peptide is incubated with pARS578antibody, whereas staining is maintained at the other phospho-AR sites.